<qa>  What is the name of the first 75 subjects tested for?This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of TritanrixTM-HepBHiberixTM. In the MencevaxTM ACWY full dose stage at 24 to 30 months of age all subjects will receive a dose of MencevaxTM ACWY. In the MencevaxTM ACWY small dose stage at 30 to 36 months of age, the first 75 subjects in each of the two centers will be tested for boostability of the MenA and MenC immune response by giving a fifth of a dose of a MencevaxTM ACWY vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. 